Nodal marginal zone B-cell lymphoma
MONDO:0019465Nodal marginal zone B-cell lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma, characterized by abnormal clonal proliferation of mature B-lymphocytes with involvement of the lymph nodes, sometimes the bone marrow, and rarely the blood. Clinically it presents with disseminated peripheral, abdominal and/or thoracic lymphadenopathy. Cytopenia and bulky tumors (greater than 5 cm) are rare. Association with Hepatitis C virus and chronic inflammation has been reported.
Also known as: Monocytoid B-cell lymphoma, NMZL, nodal marginal zone B-cell lymph., nodal marginal zone B-cell lymphoma, nodal marginal zone lymphoma
2015 clinical trials for this condition and its sub-types, 16 tagged with Nodal marginal zone B-cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New drug duo aims to control lymphoma without chemo
Disease control OngoingThis phase II trial is testing two drugs, obinutuzumab and ibrutinib, as the first treatment for people with indolent non-Hodgkin's lymphoma, a slow-growing blood cancer. The goal is to see how many patients respond to the combination. The study involves 30 participants and is no…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-stage trial tests a new three-drug combination (ibrutinib, rituximab, and bendamustine) in adults with certain types of non-Hodgkin lymphoma that have come back after prior treatment. The main goal is to find the safest dose of ibrutinib when given with the other two d…
Phase 1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Engineered T-Cells take on tough lymphoma in early trial
Disease control OngoingThis phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for marginal zone lymphoma: Chemo-Free combo shows promise
Disease control OngoingThis phase II trial tests a combination of two drugs, ibrutinib and rituximab, in people with untreated marginal zone lymphoma, a rare blood cancer. The study aims to see how many patients achieve complete remission after one year and how long they stay cancer-free. About 175 par…
Phase 2 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC